Genetic Technologies Ltd. (GENE)
| Market Cap | 39.95M |
| Revenue (ttm) | 90,642 |
| Net Income (ttm) | -5.32M |
| Shares Out | 20.43M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,725 |
| Open | 2.04 |
| Previous Close | 2.07 |
| Day's Range | 1.92 - 2.07 |
| 52-Week Range | 1.77 - 6.48 |
| Beta | 1.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GENE
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the comp...
News
Genetic Technologies Reports Q2 FY22 Cash Flow Results
Q2 momentum sets the stage for a strong FY22 Q2 momentum sets the stage for a strong FY22
GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium
MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious ...
Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent Allowance from the USPTO
MELBOURNE, Australia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious ...
Genetic Technologies Reports Q1 FY22 Results
Genetype MultiTest submitted for regulatory approval as commercialization plans gather momentum increase in cash receipts over prior quarter Genetype MultiTest submitted for regulatory approval as comme...
GENE Embarks on Breakthrough African American Collaboration for Breast Cancer as Part of Its Commitment to Ethnic Div...
Study to focus on women of African American descent for expanded polygenic risk test Study to focus on women of African American descent for expanded polygenic risk test
BelHealth Completes Asset Sale of General Genetics Corp.
FORT LAUDERDALE, Fla., Sept. 9, 2021 /PRNewswire/ -- September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the internation...
Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy
Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021 Company to present at H.C. Wainwright 23rd Annual Global Investment Conference...
Genetic Technologies Rapidly Accelerating Commercialization Plans
MELBOURNE, Australia, July 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is...
Genetic Technologies Acquires EasyDNA To Expand Into Wellness Testing
Genetic Technologies Limited (NASDAQ: GENE) has agreed to acquire EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock. EasyDNA currently sells paternity, oncology, an...
Genetic Technologies Strengthens Global Leadership in Genomics with Acquisition of EasyDNA
A global platform to market the Company's portfolio across 40 countries A global platform to market the Company's portfolio across 40 countries
Genetic Technologies Continues to Break New Ground as it Advances Development of its Predictive Risk Test for Multipl...
MELBOURNE, Australia, July 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE, "Company", "GTG"), a diversified Genomics and AI driven preventative health business, today ...
US Patent Office Grants Foundational Pharmacogenomic Patent
MELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, has be...
Infinity BiologiX, Genetic Technologies and Vault Heath launch new test to assess severity of COVID-19 in individuals
PISCATAWAY, N.J.--(BUSINESS WIRE)-- #covid19--Today, Infinity BiologiX (IBX) announces the launch of a new test meant to assess the severity of COVID-19 in individuals. The COVID-19 Risk Test is designe...
Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, today a...
Genetic Technologies appoints Mike Tonroe as CFO
MELBOURNE, Australia, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), announces the appointment of Michael Tonroe to th...
Genetic Technologies Provides Update on COVID-19 Risk Test Launch
MELBOURNE, Australia, April 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business provid...
Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
MELBOURNE, Australia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announc...
Genetic Technologies Announces Closing of $6.56 Million Registered Direct Offering
MELBOURNE, Australia, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announc...
Why Addex, Genetic Technologies And Obalon Are Moving Today
Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone...
Genetic Technologies Announces $6.56 Million Registered Direct Offering
MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announc...
GENE Stock Alert: 10 Things to Know About Genetic Technologies As Shares Rocket Higher
Shares of GENE stock are rising on Thursday morning after Genetic Technologies provided a positive update regarding two important initatives. The post GENE Stock Alert: 10 Things to Know About Genetic T...
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on fur...
Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report
MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with its interi...
Genetic Technologies to Hold Investor Webinar and Q&A Session on November 19
MELBOURNE, Australia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy M...
Genetic Technologies Provides Update on COVID-19 Risk Test
MELBOURNE, Australia, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on the dev...